Safety and Efficacy of SCM-AGH in Subjects With Moderate to Severe Atopic Dermatitis

Summary

This study consists of two phases (Phase I and Phase II). Phase II will be conducted sequentially after the safety of SCM-AGH is secured in Phase I. Phase I: Multicenter in Korea, Randomized, Open-label, Parallel arm Phase II: Multicenter in Korea, Double-blind, Placebo-controlled, Parallel arm

Timeline

Start

2020-03-24

Primary completion

2022-08-02

Completion

2022-10-26

Drugs

Indications